Invivyd, Inc. (IVVD) Secures FDA Path for COVID-19 Antibody Approval

Core Insights - Invivyd, Inc. is recognized as one of the 15 best biotech penny stocks to invest in, focusing on antibody-based therapies for serious viral infections, including COVID-19 and influenza [1] - The company has entered a strategic agreement with the FDA to utilize a single Phase 2/3 trial for the full approval of its lead COVID-19 monoclonal antibody candidate, VYD2311, enhancing its position in adaptable COVID-19 therapies [2] - Invivyd has bolstered its financial standing through a $57.5 million public offering, which will support the development of VYD2311 and expand its infectious disease pipeline [3] Financial Developments - The public offering involved the issuance of over 89 million shares, with proceeds aimed at funding the continued development of VYD2311 and other viral threats [3] - Following the announcement of the public offering and FDA agreement, investor confidence surged, resulting in a stock price increase of over 90% [3] Regulatory and Research Validation - VYD2311 has been recognized in the SPEAR Study Group's recommended Long COVID antibody study design, indicating its potential beyond just prevention [4]